首页 > 最新文献

Experimental oncology最新文献

英文 中文
CASE OF THE TRANSFORMATION OF PSORIASIS INTO CUTANEOUS T-CELL LYMPHOMA. 牛皮癣转化为皮肤 t 细胞淋巴瘤的病例。
Pub Date : 2024-05-31 DOI: 10.15407/exp-oncology.2024.01.068
V Tkach, O Aleksandruk, І Kostyshyn, M Voloshynovych, G Girnyk, S Romanchuk

Psoriasis is a long-known skin pathology, the incidence of which is constantly rising, though it is not possible to clearly establish the trend due to the differences in the research design. In recent years, the number of cases among children and adolescents has increased. Psoriasis becomes more aggressive, severe forms are more common. It can be combined with other diseases but is rarely complicated. Isolated cases of the transformation of psoriatic plaques into skin cancer have already been described in the literature. Probable causes were the long-term use of photosensitizers and phototherapy, naphthalene, and tar. However, in general, the risk of the malignant recurrence in patients with psoriasis does not increase significantly. We present a clinical observation of the transformation of psoriasis into cutaneous T-cell lymphoma in a patient with more than 37 years of psoriasis experience, where on the background of typical psoriatic rashes, fungal growths of doughy consistency appeared, which were initially misinterpreted as a warty form of psoriasis. Based on the data of additional methods of examination and the results of histological examination, the diagnosis was clarified. Specific treatment was prescribed, which proved its effectiveness. The probable causes of degeneration, in our opinion, are prolonged irritating external therapy and excessive insolation.

牛皮癣是一种久负盛名的皮肤病,其发病率不断上升,但由于研究设计的差异,无法明确确定其发病趋势。近年来,儿童和青少年中的发病人数有所增加。银屑病变得更具侵袭性,严重的银屑病更为常见。牛皮癣可合并其他疾病,但很少并发。文献中已经描述了银屑病斑块转变为皮肤癌的孤立病例。可能的原因是长期使用光敏剂和光疗、萘和焦油。不过,一般来说,银屑病患者恶性肿瘤复发的风险并没有明显增加。我们介绍了一位有超过 37 年银屑病病史的患者银屑病转化为皮肤 T 细胞淋巴瘤的临床观察结果,该患者在典型银屑病皮疹的基础上出现了稠厚的真菌生长,最初被误认为是疣状银屑病。根据其他检查方法的数据和组织学检查的结果,明确了诊断。对症下药,疗效显著。我们认为,退化的可能原因是长期的刺激性外部治疗和过度日晒。
{"title":"CASE OF THE TRANSFORMATION OF PSORIASIS INTO CUTANEOUS T-CELL LYMPHOMA.","authors":"V Tkach, O Aleksandruk, І Kostyshyn, M Voloshynovych, G Girnyk, S Romanchuk","doi":"10.15407/exp-oncology.2024.01.068","DOIUrl":"10.15407/exp-oncology.2024.01.068","url":null,"abstract":"<p><p>Psoriasis is a long-known skin pathology, the incidence of which is constantly rising, though it is not possible to clearly establish the trend due to the differences in the research design. In recent years, the number of cases among children and adolescents has increased. Psoriasis becomes more aggressive, severe forms are more common. It can be combined with other diseases but is rarely complicated. Isolated cases of the transformation of psoriatic plaques into skin cancer have already been described in the literature. Probable causes were the long-term use of photosensitizers and phototherapy, naphthalene, and tar. However, in general, the risk of the malignant recurrence in patients with psoriasis does not increase significantly. We present a clinical observation of the transformation of psoriasis into cutaneous T-cell lymphoma in a patient with more than 37 years of psoriasis experience, where on the background of typical psoriatic rashes, fungal growths of doughy consistency appeared, which were initially misinterpreted as a warty form of psoriasis. Based on the data of additional methods of examination and the results of histological examination, the diagnosis was clarified. Specific treatment was prescribed, which proved its effectiveness. The probable causes of degeneration, in our opinion, are prolonged irritating external therapy and excessive insolation.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SYSTEMIC INFLAMMATORY INDICES IN PATIENTS WITH MALIGNANT GLIOMAS AND EFFECTS OF PLATELET SECRETOME IN VITRO. 恶性胶质瘤患者的全身炎症指数和血小板体外分泌物的影响。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.409
V Rozumenko, L Liubich, E Pedachenko, L Staino, D Egorova, L Kot, T Malysheva

Background: To date, no significant clinical progress has been achieved in the treatment of brain malignant gliomas (MG), and the active search for non-invasive circulating biomarkers continues. The prognostic significance of the ratio of the main peripheral blood cell populations of patients with MG is evaluated. Considerable attention is paid to the secretome of platelets (Pt) of peripheral blood.

Aim: To evaluate the indicators of the peripheral blood cell population ratios in patients with brain MG and to study the influence of the secretome of Pt (SPt) of the peripheral blood of patients with brain MG in cell cultures in vitro.

Materials and methods: We studied samples of peripheral blood from patients with glioma CNS WHO grade G2 (n = 5), G3 (n = 12), and G4 (n = 20). The peripheral blood cell counts were analyzed in the preoperative period on an automatic hematology analyzer. The in vitro study of SPt was performed on the U251 human glioblastoma cell line cultured with SPt from MG patients or SPt pre-incubated with anti-TGF-β1 antibody. Cell cultures were observed for 72 h, and mitotic index (MI) was calculated.

Results: In MG patients, the count of peripheral blood leukocytes and neutrophils increased (p < 0.05). The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) increased by 2-3 times compared to control. Nevertheless, correlation analysis did not reveal significant relationships between quantitative indicators of peripheral blood cells and the tumor malignancy degree in MG patients. The MI in U251 cells increased under the influence of SPt from patients with MG (p < 0.021), correlated with the tumor degree of malignancy (r = 0.246, p = 0.014). Pre-incubation of SPt with anti-TGF-β1 antibody tends to neutralize this promitotic effect.

Conclusion: In MG patients, the integral indicators of NLR and SII increased but no significant relationship with the degree of tumor malignancy was found. In U251 cells, promitotic effects of SPt of MG patients partially decreased by anti-TGF-β1 antibody.

背景:迄今为止,脑恶性胶质瘤(MG)的临床治疗尚未取得重大进展,人们仍在积极寻找非侵入性循环生物标志物。本研究评估了 MG 患者主要外周血细胞群比例的预后意义。目的:评估脑部 MG 患者外周血细胞群比率指标,研究脑部 MG 患者外周血血小板分泌物(Pt)对体外细胞培养的影响:我们研究了中枢神经系统胶质瘤 WHO 分级 G2(5 例)、G3(12 例)和 G4(20 例)患者的外周血样本。外周血细胞计数在术前通过自动血液分析仪进行分析。SPt 的体外研究是在用来自 MG 患者的 SPt 或与抗肿瘤坏死因子-β1 抗体预孵育的 SPt 培养的 U251 人胶质母细胞瘤细胞系上进行的。观察细胞培养 72 小时,并计算有丝分裂指数(MI):结果:MG 患者的外周血白细胞和中性粒细胞数量增加(P < 0.05)。与对照组相比,中性粒细胞与淋巴细胞比值(NLR)和全身免疫炎症指数(SII)增加了 2-3 倍。然而,相关性分析并未发现外周血细胞定量指标与 MG 患者肿瘤恶性程度之间存在显著关系。U251 细胞中的 MI 在 MG 患者 SPt 的影响下增加(p < 0.021),与肿瘤恶性程度相关(r = 0.246,p = 0.014)。用抗 TGF-β1 抗体预孵育 SPt 有中和这种促癌作用的趋势:结论:在 MG 患者中,NLR 和 SII 的积分指标升高,但与肿瘤恶性程度无明显关系。在 U251 细胞中,抗 TGF-β1 抗体可部分降低 MG 患者 SPt 的促癌作用。
{"title":"SYSTEMIC INFLAMMATORY INDICES IN PATIENTS WITH MALIGNANT GLIOMAS AND EFFECTS OF PLATELET SECRETOME IN VITRO.","authors":"V Rozumenko, L Liubich, E Pedachenko, L Staino, D Egorova, L Kot, T Malysheva","doi":"10.15407/exp-oncology.2023.04.409","DOIUrl":"10.15407/exp-oncology.2023.04.409","url":null,"abstract":"<p><strong>Background: </strong>To date, no significant clinical progress has been achieved in the treatment of brain malignant gliomas (MG), and the active search for non-invasive circulating biomarkers continues. The prognostic significance of the ratio of the main peripheral blood cell populations of patients with MG is evaluated. Considerable attention is paid to the secretome of platelets (Pt) of peripheral blood.</p><p><strong>Aim: </strong>To evaluate the indicators of the peripheral blood cell population ratios in patients with brain MG and to study the influence of the secretome of Pt (SPt) of the peripheral blood of patients with brain MG in cell cultures in vitro.</p><p><strong>Materials and methods: </strong>We studied samples of peripheral blood from patients with glioma CNS WHO grade G2 (n = 5), G3 (n = 12), and G4 (n = 20). The peripheral blood cell counts were analyzed in the preoperative period on an automatic hematology analyzer. The in vitro study of SPt was performed on the U251 human glioblastoma cell line cultured with SPt from MG patients or SPt pre-incubated with anti-TGF-β1 antibody. Cell cultures were observed for 72 h, and mitotic index (MI) was calculated.</p><p><strong>Results: </strong>In MG patients, the count of peripheral blood leukocytes and neutrophils increased (p < 0.05). The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) increased by 2-3 times compared to control. Nevertheless, correlation analysis did not reveal significant relationships between quantitative indicators of peripheral blood cells and the tumor malignancy degree in MG patients. The MI in U251 cells increased under the influence of SPt from patients with MG (p < 0.021), correlated with the tumor degree of malignancy (r = 0.246, p = 0.014). Pre-incubation of SPt with anti-TGF-β1 antibody tends to neutralize this promitotic effect.</p><p><strong>Conclusion: </strong>In MG patients, the integral indicators of NLR and SII increased but no significant relationship with the degree of tumor malignancy was found. In U251 cells, promitotic effects of SPt of MG patients partially decreased by anti-TGF-β1 antibody.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TUMOR MICROENVIRONMENT-ASSOCIATED miR-7-5p, miR-19a-3p, AND miR-23b-3p EXPRESSION IN PROSTATE CANCER WITH DIFFERENT PROGRESSION RISK. 肿瘤微环境相关的 miR-7-5p、miR-19a-3p 和 miR-23b-3p 在不同进展风险的前列腺癌中的表达。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.432
T Borikun, O Mushii, A Pavlova, T Burda, T Zadvornyi

Background: The tumor microenvironment (TME) plays an important role in the occurrence and progression of prostate cancer (PCa). At the same time, the mechanisms and features of the interaction between tumor cells and individual components of the TME in PCa remain not fully elucidated. The aim was to study the expression levels of tumor-associated miR-7-5p, miR-19a-3p, and miR-23b-3p in the PCa tissue and to analyze their relationship with the features of TME.

Materials and methods: The work is based on the analysis of the results of the examination and treatment of 50 patients with PCa of stages II-IV. The expression of miRNA in the PCa tissue was analyzed by the real-time polymerase chain reaction. The expression of alpha-smooth muscle actin (α-SMA), vimentin (VIM), and CD68 in PCa tissue was determined by the immunohistochemical method. The identification of mast cells in the PCa tissue was assessed by the histochemical method.

Results: The analysis of the expression levels of tumor-associated miRNAs demonstrated that the tumor tissue of patients with a high risk of PCa progression was characterized by 4.93 (p < 0.01) and 8.97 (p < 0.05) times higher levels of miR-19a-3p and miR-23b-3p, respectively, compared to similar indicators in the group of patients with a low risk of PCa progression. The levels of miR-7-5p and miR-19a-3p expression in the PCa tissue correlated with the expression level of α-SMA (r = 0.49 and r = 0.45, respectively; p < 0.05) and VIM (r = 0.45 and r = 0.46; respectively, p < 0.05). A direct relationship (r = 0.44; p < 0.05) was established between the level of miR-7-5p expression and the degree of infiltration of the prostate gland tissue by tumor-associated macrophages.

Conclusions: The features of the expression of tumor-associated miR-7-5p, miR-19a-3p, and miR-23b-3p indicated the prospect of their use as markers of the aggressiveness of the PCa course.

背景:肿瘤微环境(TME)在前列腺癌(PCa)的发生和发展中起着重要作用。与此同时,PCa 中肿瘤细胞与肿瘤微环境中单个成分之间相互作用的机制和特征仍未完全阐明。本研究旨在研究PCa组织中肿瘤相关miR-7-5p、miR-19a-3p和miR-23b-3p的表达水平,并分析它们与TME特征的关系:该研究基于对 50 例 II-IV 期 PCa 患者的检查和治疗结果的分析。实时聚合酶链反应分析了 PCa 组织中 miRNA 的表达。免疫组化法测定了 PCa 组织中α-平滑肌肌动蛋白(α-SMA)、波形蛋白(VIM)和 CD68 的表达。PCa 组织中肥大细胞的鉴定采用组织化学方法:肿瘤相关miRNA的表达水平分析表明,与低风险PCa患者组的类似指标相比,高风险PCa患者肿瘤组织中的miR-19a-3p和miR-23b-3p水平分别高出4.93倍(p<0.01)和8.97倍(p<0.05)。PCa组织中miR-7-5p和miR-19a-3p的表达水平与α-SMA(r=0.49和r=0.45,p<0.05)和VIM(r=0.45和r=0.46,p<0.05)的表达水平相关。miR-7-5p的表达水平与肿瘤相关巨噬细胞浸润前列腺组织的程度之间存在直接关系(r = 0.44;p < 0.05):结论:肿瘤相关 miR-7-5p、miR-19a-3p 和 miR-23b-3p 的表达特征表明,它们有望被用作 PCa 病程侵袭性的标志物。
{"title":"TUMOR MICROENVIRONMENT-ASSOCIATED miR-7-5p, miR-19a-3p, AND miR-23b-3p EXPRESSION IN PROSTATE CANCER WITH DIFFERENT PROGRESSION RISK.","authors":"T Borikun, O Mushii, A Pavlova, T Burda, T Zadvornyi","doi":"10.15407/exp-oncology.2023.04.432","DOIUrl":"10.15407/exp-oncology.2023.04.432","url":null,"abstract":"<p><strong>Background: </strong>The tumor microenvironment (TME) plays an important role in the occurrence and progression of prostate cancer (PCa). At the same time, the mechanisms and features of the interaction between tumor cells and individual components of the TME in PCa remain not fully elucidated. The aim was to study the expression levels of tumor-associated miR-7-5p, miR-19a-3p, and miR-23b-3p in the PCa tissue and to analyze their relationship with the features of TME.</p><p><strong>Materials and methods: </strong>The work is based on the analysis of the results of the examination and treatment of 50 patients with PCa of stages II-IV. The expression of miRNA in the PCa tissue was analyzed by the real-time polymerase chain reaction. The expression of alpha-smooth muscle actin (α-SMA), vimentin (VIM), and CD68 in PCa tissue was determined by the immunohistochemical method. The identification of mast cells in the PCa tissue was assessed by the histochemical method.</p><p><strong>Results: </strong>The analysis of the expression levels of tumor-associated miRNAs demonstrated that the tumor tissue of patients with a high risk of PCa progression was characterized by 4.93 (p < 0.01) and 8.97 (p < 0.05) times higher levels of miR-19a-3p and miR-23b-3p, respectively, compared to similar indicators in the group of patients with a low risk of PCa progression. The levels of miR-7-5p and miR-19a-3p expression in the PCa tissue correlated with the expression level of α-SMA (r = 0.49 and r = 0.45, respectively; p < 0.05) and VIM (r = 0.45 and r = 0.46; respectively, p < 0.05). A direct relationship (r = 0.44; p < 0.05) was established between the level of miR-7-5p expression and the degree of infiltration of the prostate gland tissue by tumor-associated macrophages.</p><p><strong>Conclusions: </strong>The features of the expression of tumor-associated miR-7-5p, miR-19a-3p, and miR-23b-3p indicated the prospect of their use as markers of the aggressiveness of the PCa course.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INTRA-ARTERIAL CHEMOTHERAPY AS A CLINICAL OPTION FOR METASTATIC COLORECTAL CANCER: CONVERSION OF INOPERABLE LIVER METASTASES TO OPERABLE ILLUSTRATED WITH A CLINICAL CASE. 动脉内化疗作为转移性结直肠癌的临床选择:通过一个临床病例说明无法手术的肝转移灶转为可手术。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.515
K Cherchenko, A Lukashenko, Yu Ostapenko, V Patsko, M Vinohradova, K Valikhnovska, S Pamanska

Colorectal cancer exerts a very high level of liver metastases, even on primary diagnosis, with 80%-90% unresectable nodules. At the same time, the possibility of resection has a significant impact on survival: 5-year survival is 6%-10% without liver surgery and up to 30% upon resection of liver metastases. Finding ways to improve resectability is a topical search for doctors all over the world. One of the promising methods to convert unresectable liver metastases of colorectal cancer into resectable ones is a hepatic artery infusion, or intra-arterial chemotherapy allowing for the delivery of cytotoxic drugs directly to the common hepatic artery via catheter or pump with decreased systemic toxicity and increased local drug concentration. In this article, we discuss the literature data on the impact of intra-arterial chemotherapy on the resectability of colorectal metastases in the liver and present the results of the successful clinical case. The literature shows a positive impact of the hepatic artery infusion on the resectability of hepatic metastases of colorectal cancer. The National Cancer Institute (Ukraine) has its own experience in hepatic artery infusion with further resection of primary-unresectable colorectal metastases in the liver. In our clinical case, a patient with liver-limited metastasis of colorectal cancer was initially inoperable due to the size of tumor lesions and an insufficient residual volume of the liver. Hepatic artery infusion tactics was chosen for this patient. The patient received six cycles of intra-arterial chemotherapy, namely five FOLFOX cycles and one 5-FU cycle, and then met the resectability criteria. Also, it is important to notice that the case demonstrates chemoresistance overcoming, since the patient had disease progression before, following systemically administered XELOX, and the period until readmission of the drugs was less than 6 months. So, hepatic artery infusion can be considered a promising method to convert unresectable liver metastases of colorectal cancer into resectable ones for highly selected patients.

结直肠癌的肝转移率非常高,即使在初诊时也是如此,80%-90%的结节无法切除。与此同时,切除的可能性对患者的生存也有重大影响:不进行肝脏手术的患者 5 年生存率为 6%-10%,而切除肝脏转移灶的患者 5 年生存率则高达 30%。寻找提高可切除性的方法是全世界医生的热门话题。将结直肠癌不可切除的肝转移灶转化为可切除的肝转移灶的有效方法之一是肝动脉输注或动脉内化疗,通过导管或泵将细胞毒性药物直接输送到肝总动脉,降低全身毒性,提高局部药物浓度。本文讨论了动脉内化疗对肝内结直肠转移瘤可切除性影响的文献数据,并介绍了成功的临床病例结果。文献显示,肝动脉输注对结直肠癌肝转移灶的可切除性有积极影响。乌克兰国家癌症研究所(National Cancer Institute)在肝动脉灌注并进一步切除肝脏内原发性不可切除的结直肠癌转移瘤方面有自己的经验。在我们的临床病例中,一名结直肠癌肝转移患者最初因肿瘤病灶大小和肝脏残余容积不足而无法手术。该患者选择了肝动脉输注战术。患者接受了六个周期的动脉内化疗,即五个 FOLFOX 周期和一个 5-FU 周期,随后达到了可切除标准。另外,需要注意的是,该病例体现了化疗耐药性的克服,因为患者之前在全身用药 XELOX 后疾病出现了进展,而直到再次用药的时间还不到 6 个月。因此,对于经过严格筛选的患者,肝动脉输注被认为是将结直肠癌不可切除的肝转移灶转化为可切除肝转移灶的一种有前途的方法。
{"title":"INTRA-ARTERIAL CHEMOTHERAPY AS A CLINICAL OPTION FOR METASTATIC COLORECTAL CANCER: CONVERSION OF INOPERABLE LIVER METASTASES TO OPERABLE ILLUSTRATED WITH A CLINICAL CASE.","authors":"K Cherchenko, A Lukashenko, Yu Ostapenko, V Patsko, M Vinohradova, K Valikhnovska, S Pamanska","doi":"10.15407/exp-oncology.2023.04.515","DOIUrl":"10.15407/exp-oncology.2023.04.515","url":null,"abstract":"<p><p>Colorectal cancer exerts a very high level of liver metastases, even on primary diagnosis, with 80%-90% unresectable nodules. At the same time, the possibility of resection has a significant impact on survival: 5-year survival is 6%-10% without liver surgery and up to 30% upon resection of liver metastases. Finding ways to improve resectability is a topical search for doctors all over the world. One of the promising methods to convert unresectable liver metastases of colorectal cancer into resectable ones is a hepatic artery infusion, or intra-arterial chemotherapy allowing for the delivery of cytotoxic drugs directly to the common hepatic artery via catheter or pump with decreased systemic toxicity and increased local drug concentration. In this article, we discuss the literature data on the impact of intra-arterial chemotherapy on the resectability of colorectal metastases in the liver and present the results of the successful clinical case. The literature shows a positive impact of the hepatic artery infusion on the resectability of hepatic metastases of colorectal cancer. The National Cancer Institute (Ukraine) has its own experience in hepatic artery infusion with further resection of primary-unresectable colorectal metastases in the liver. In our clinical case, a patient with liver-limited metastasis of colorectal cancer was initially inoperable due to the size of tumor lesions and an insufficient residual volume of the liver. Hepatic artery infusion tactics was chosen for this patient. The patient received six cycles of intra-arterial chemotherapy, namely five FOLFOX cycles and one 5-FU cycle, and then met the resectability criteria. Also, it is important to notice that the case demonstrates chemoresistance overcoming, since the patient had disease progression before, following systemically administered XELOX, and the period until readmission of the drugs was less than 6 months. So, hepatic artery infusion can be considered a promising method to convert unresectable liver metastases of colorectal cancer into resectable ones for highly selected patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY. 非特异性 T 细胞淋巴瘤:单中心研究结果。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.474
I Kriachok, I Tytorenko, N Shudrak, O Aleksik, Ya Stepanishyna, T Kadnikova, Ya Pastushenko, N Shokun, T Rudiyk, M Bushuieva

Background: The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response.

Patients and methods: An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP - cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18).

Results: The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (> 65%) was a negative prognostic factor.

Conclusions: The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.

背景:非特异性外周T细胞淋巴瘤(PTCL-NOS)是外周T细胞淋巴瘤(PTCL)中最常见的亚型。它约占所有 PTCL 的 25%,占所有淋巴瘤的 15%以上。文章介绍了乌克兰首次对PTCL-NOS患者进行前瞻性研究的结果。研究的目的是分析 PTCL 患者的发病率和所接受的治疗,评估总生存期和无进展生存期,并确定预测治疗反应的因素:对2018年2月至今确诊为外周PTCL-NOS的31名患者的数据进行了分析。T细胞淋巴肿瘤根据2016年WHO分类进行诊断。治疗方案与ESMO和NCCN指南一致。90%以上的患者接受了以蒽环类药物为基础的治疗方案(CHOP;CHOEP--环磷酰胺、多柔比星、依托泊苷、长春新碱、泼尼松)。38.70%的患者(12 人)采用了以 CHOP 为基础的初始治疗方案,58.06%的患者(18 人)添加了依托泊苷:根据恶性淋巴瘤反应标准(Cheson,2008年,2014年)评估反应。治疗总反应率为58.06%(n = 18),其中29.03%的患者有完全反应,29.03%的患者有部分反应。3.44%的患者病情稳定,41.37%的患者病情恶化。12个月和24个月的生存率分别为75.44%和50.81%。12个月和24个月无进展生存率分别为47.68%和33.1%。Ki-67过表达(> 65%)是一个负面预后因素:结论:乌克兰的一项人口研究得出的PTCL治疗结果与欧洲其他研究的结果相似,但所有这些研究的结果都不尽如人意。需要开展进一步研究,制定新的检查和治疗策略,以改善治疗效果。重点应放在对具有有利和不利临床因素的 PTCL 患者的一线治疗效果进行比较的务实临床试验上。
{"title":"NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.","authors":"I Kriachok, I Tytorenko, N Shudrak, O Aleksik, Ya Stepanishyna, T Kadnikova, Ya Pastushenko, N Shokun, T Rudiyk, M Bushuieva","doi":"10.15407/exp-oncology.2023.04.474","DOIUrl":"10.15407/exp-oncology.2023.04.474","url":null,"abstract":"<p><strong>Background: </strong>The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response.</p><p><strong>Patients and methods: </strong>An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP - cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18).</p><p><strong>Results: </strong>The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (> 65%) was a negative prognostic factor.</p><p><strong>Conclusions: </strong>The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROGNOSTIC SIGNIFICANCE OF microRNA-100, -125b, AND -200b IN PATIENTS WITH COLORECTAL CANCER. microRNA-100、-125b 和 -200b 在色素性直肠癌患者中的预后意义。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.443
S Maliborska, V Holotiuk, Y Partykevych, O Rossylna

Background: The discovery of new markers for colorectal cancer (CRC) is of paramount importance for improving the diagnosis, prognosis, and treatment of this disease. CRC is the third most common cancer worldwide and the second leading cause of cancer-related deaths. Early detection and treatment are crucial for improving patient outcomes, but current screening methods are not foolproof. Additionally, there is a need for better prognostic markers to identify patients at high risk of recurrence or metastasis, who may benefit from more aggressive treatment.

Objectives: To analyze the expression profile of miR-100, miR-125b, and miR-200b in the blood serum of CRC patients and assess its correlation with the clinicopathological factors of cancer course.

Materials and methods: Twenty blood serum samples from CRC patients were analyzed by the real-time polymerase chain reaction for miR-100, miR-125b, and miR-200b expressions. The results were normalized and then analyzed using statistical tests.

Results: According to our results, miR-125b and -200b expressions correlate with T (r = -0.51 and 0.6, respectively, p < 0.05) and N (r = 0.47 and -0.52, respectively, p < 0.05). Also, miR-125b levels were 1.56 times higher and mir- 200b - 1.59 times lower in patients with metastases in the regional lymph nodes.

Conclusions: Observed levels of miR-125b and -200b in correlation with tumor stage and lymph node metastasis among CRC patients demonstrate their potential clinical utility as minimally invasive biomarkers for the prognosis of cancer course. Therefore, further validation studies with larger participant cohorts are necessary.

背景:发现结直肠癌(CRC)的新标记物对于改善该疾病的诊断、预后和治疗至关重要。CRC 是全球第三大常见癌症,也是癌症相关死亡的第二大原因。早期发现和治疗对改善患者预后至关重要,但目前的筛查方法并非万无一失。此外,还需要更好的预后标志物来识别复发或转移风险高的患者,这些患者可能会从更积极的治疗中获益:分析 CRC 患者血清中 miR-100、miR-125b 和 miR-200b 的表达谱,并评估其与癌症病程的临床病理因素的相关性:用实时聚合酶链反应分析 20 份 CRC 患者血清样本中 miR-100、miR-125b 和 miR-200b 的表达。对结果进行归一化处理,然后用统计学检验进行分析:结果显示,miR-125b和-200b的表达与T(r=-0.51和0.6,p<0.05)和N(r=0.47和-0.52,p<0.05)相关。此外,在区域淋巴结转移的患者中,miR-125b水平高1.56倍,mir- 200b低1.59倍:结论:观察到的 miR-125b 和 -200b 水平与 CRC 患者的肿瘤分期和淋巴结转移的相关性表明,它们作为微创生物标记物对癌症病程预后具有潜在的临床实用性。因此,有必要进行更大规模的验证研究。
{"title":"PROGNOSTIC SIGNIFICANCE OF microRNA-100, -125b, AND -200b IN PATIENTS WITH COLORECTAL CANCER.","authors":"S Maliborska, V Holotiuk, Y Partykevych, O Rossylna","doi":"10.15407/exp-oncology.2023.04.443","DOIUrl":"10.15407/exp-oncology.2023.04.443","url":null,"abstract":"<p><strong>Background: </strong>The discovery of new markers for colorectal cancer (CRC) is of paramount importance for improving the diagnosis, prognosis, and treatment of this disease. CRC is the third most common cancer worldwide and the second leading cause of cancer-related deaths. Early detection and treatment are crucial for improving patient outcomes, but current screening methods are not foolproof. Additionally, there is a need for better prognostic markers to identify patients at high risk of recurrence or metastasis, who may benefit from more aggressive treatment.</p><p><strong>Objectives: </strong>To analyze the expression profile of miR-100, miR-125b, and miR-200b in the blood serum of CRC patients and assess its correlation with the clinicopathological factors of cancer course.</p><p><strong>Materials and methods: </strong>Twenty blood serum samples from CRC patients were analyzed by the real-time polymerase chain reaction for miR-100, miR-125b, and miR-200b expressions. The results were normalized and then analyzed using statistical tests.</p><p><strong>Results: </strong>According to our results, miR-125b and -200b expressions correlate with T (r = -0.51 and 0.6, respectively, p < 0.05) and N (r = 0.47 and -0.52, respectively, p < 0.05). Also, miR-125b levels were 1.56 times higher and mir- 200b - 1.59 times lower in patients with metastases in the regional lymph nodes.</p><p><strong>Conclusions: </strong>Observed levels of miR-125b and -200b in correlation with tumor stage and lymph node metastasis among CRC patients demonstrate their potential clinical utility as minimally invasive biomarkers for the prognosis of cancer course. Therefore, further validation studies with larger participant cohorts are necessary.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN BREAST CANCER PATIENTS OF YOUNG AGE. 年轻乳腺癌患者中 miR-145、-182、-21、-27a、-29b 和 -34a 的表达谱。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.421
V Chekhun, T Borikun, O Mushii, T Zadvornyi, О Martyniuk, E Kashuba, V Bazas, S Hrybach, M Krotevych, S Lyalkin, N Lukianova

Background: Breast cancer (BC) in young women remains a significant public health concern. While progress has been made in understanding the etiology, diagnosis, and treatment of BC in this population, challenges persist. The identification and utilization of prognostic biomarkers offer valuable tools for tailoring treatment strategies and improving outcomes for BC patients.

Aim: To evaluate the relationship between the expression of tumor-associated microRNAs and the clinical and pathological features of BC in young patients.

Materials and methods: The work is based on the results of the examination and treatment of 50 women younger than 45 years with stage I-II BC. miR-145, -182, -21, -27a, -29b, and -34a expression in tumor samples was analyzed by the real-time reverse transcription polymerase chain reaction.

Results: Higher expression of miR-182, -21, and -29b and lower levels of miR-27a were associated with tumor stage in young BC patients. Patients without lymph node metastases (N0) had significantly higher levels of miR-182, -27a, and -34a and lower levels of miR-29b compared to N1 cases (p < 0.05). Expression of miR-145, -182, -21, -27a, and -29b was associated with molecular BC subtypes.

Conclusion: Obtained results show that a high malignancy degree of BC in young women is associated with an increase in the miR-182, -21, -29b, and -34a expressions and a decrease in the miR-27a level in the tumor tissue, which indicates the prospects of the use of them for predicting the aggressiveness of the disease.

背景:年轻女性患乳腺癌(BC)仍然是一个重大的公共卫生问题。虽然在了解年轻女性乳腺癌的病因、诊断和治疗方面取得了进展,但挑战依然存在。预后生物标志物的鉴定和利用为调整治疗策略和改善BC患者的预后提供了宝贵的工具。目的:评估肿瘤相关microRNAs的表达与年轻患者BC的临床和病理特征之间的关系:通过实时逆转录聚合酶链反应分析肿瘤样本中miR-145、-182、-21、-27a、-29b和-34a的表达情况:结果:在年轻的 BC 患者中,miR-182、-21 和 -29b 的表达量较高,而 miR-27a 的表达量较低,这与肿瘤分期有关。与 N1 病例相比,无淋巴结转移(N0)患者的 miR-182、-27a 和 -34a 水平明显较高,而 miR-29b 水平较低(p < 0.05)。miR-145、-182、-21、-27a和-29b的表达与BC分子亚型有关:结论:研究结果表明,年轻女性BC恶性程度高与肿瘤组织中miR-182、-21、-29b和-34a表达量的增加以及miR-27a水平的降低有关,这预示着利用它们预测疾病侵袭性的前景。
{"title":"EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN BREAST CANCER PATIENTS OF YOUNG AGE.","authors":"V Chekhun, T Borikun, O Mushii, T Zadvornyi, О Martyniuk, E Kashuba, V Bazas, S Hrybach, M Krotevych, S Lyalkin, N Lukianova","doi":"10.15407/exp-oncology.2023.04.421","DOIUrl":"10.15407/exp-oncology.2023.04.421","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) in young women remains a significant public health concern. While progress has been made in understanding the etiology, diagnosis, and treatment of BC in this population, challenges persist. The identification and utilization of prognostic biomarkers offer valuable tools for tailoring treatment strategies and improving outcomes for BC patients.</p><p><strong>Aim: </strong>To evaluate the relationship between the expression of tumor-associated microRNAs and the clinical and pathological features of BC in young patients.</p><p><strong>Materials and methods: </strong>The work is based on the results of the examination and treatment of 50 women younger than 45 years with stage I-II BC. miR-145, -182, -21, -27a, -29b, and -34a expression in tumor samples was analyzed by the real-time reverse transcription polymerase chain reaction.</p><p><strong>Results: </strong>Higher expression of miR-182, -21, and -29b and lower levels of miR-27a were associated with tumor stage in young BC patients. Patients without lymph node metastases (N0) had significantly higher levels of miR-182, -27a, and -34a and lower levels of miR-29b compared to N1 cases (p < 0.05). Expression of miR-145, -182, -21, -27a, and -29b was associated with molecular BC subtypes.</p><p><strong>Conclusion: </strong>Obtained results show that a high malignancy degree of BC in young women is associated with an increase in the miR-182, -21, -29b, and -34a expressions and a decrease in the miR-27a level in the tumor tissue, which indicates the prospects of the use of them for predicting the aggressiveness of the disease.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Volodymyr Oleksiyovych SHLYAKHOVENKO. 沃洛德梅尔-奥列克西约维奇-什利亚霍文科。
Pub Date : 2024-02-03

With deep sadness, we announce that on December 10, 2023, at the age of 86 passed away an outstanding Ukrainian scientist in the field of oncology, analytical enzymology, and pharmacology, a Laureate of the State Prize of Ukraine for Science and Technology, a member of the Federation of European Biochemical Societies, a member of the State Expert Center of the Ministry of Health of Ukraine, Doctor of Medical Sciences, Professor Volodymyr Oleksiyovych SHLYAKHOVENKO.

我们沉痛地宣布,2023 年 12 月 10 日,乌克兰肿瘤学、分析酶学和药理学领域的杰出科学家,乌克兰国家科技奖获得者,欧洲生化学会联合会成员,乌克兰卫生部国家专家中心成员,医学博士沃洛德梅尔-奥列克西约维奇-什利亚霍文科教授逝世,享年 86 岁。
{"title":"Volodymyr Oleksiyovych SHLYAKHOVENKO.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With deep sadness, we announce that on December 10, 2023, at the age of 86 passed away an outstanding Ukrainian scientist in the field of oncology, analytical enzymology, and pharmacology, a Laureate of the State Prize of Ukraine for Science and Technology, a member of the Federation of European Biochemical Societies, a member of the State Expert Center of the Ministry of Health of Ukraine, Doctor of Medical Sciences, Professor Volodymyr Oleksiyovych SHLYAKHOVENKO.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
СANCER INCIDENCE IN UKRAINE: TRENDS IN 2010-2019 AND THE IMPACT OF COVID-19 PANDEMIC. 乌克兰的癌症发病率:2010-2019 年的趋势和 COVID-19 大流行的影响。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.463
Yu I Michailovich, O V Sumkina, Ye L Gorokh

Background: In 2020, a sharp decrease in the number of new cancer cases was registered in Ukraine in the setting of the quarantine restrictions due to the COVID-19 pandemic, which contrasted with the previous trends.

Aim: To study trends of cancer incidence rates in Ukraine in the recent decade and to assess the impact of COVID-19 pandemic on cancer detection in 2020.

Materials and methods: Records on cancer cases diagnosed during 2010-2020 (n = 1,498,911) from the database of the National Cancer Registry of Ukraine were used; the data being submitted early in 2022. Trends of the age-standardized incidence rates in 2010-2019 were estimated by the Joinpoint Regression Program.

Results: During 2010-2019, the incidence rates increased (p < 0.05) for colon, prostate, and pharyngeal cancers in males and for colon, thyroid, and pancreas in females with the rates of other prevalent cancers being stable or decreasing (lung and larynx in males, cervix and rectum in females, stomach in both genders); the incidence increased mainly at the expense of the population aged 60-74 years. A significant decrease in cancer incidence was in males aged 40-59 years. In 2020, the serious negative impact of COVID-19 outbreak on the timely detection of cancer occurred in all adult age groups of the Ukrainian population and involved all the most common cancers. The most pronounced diminution of the incidence rate was observed for non-melanoma skin cancers (by 35.9%- 37.9%); the decrements of the rates for other prevalent cancers varied from -23.0% (prostate gland) to -9.7% (pharynx) in males and from -21.2% (kidney) to -9.1% (pancreas) in females, the greatest ones being in the population aged 75+.

Conclusions: The sharp drop of the cancer incidence rates registered in Ukraine 2020 is evidently the result of the limited access to healthcare facilities as well as the reduced oncological alertness of the population due to the predominant focus on COVID-19 during the pandemic. However, it is not a manifestation of a decrease in cancer incidence as such. In the following years, this may increase the proportion of advanced-stage diagnoses, the load on the cancer care system, and cancer mortality in the Ukrainian population. An evaluation of the short-termand long-term effects of the COVID-19 pandemic on the cancer burden in Ukraine requires further monitoring.

背景:目的:研究近十年来乌克兰癌症发病率的变化趋势,评估 COVID-19 大流行对 2020 年癌症检测的影响:使用乌克兰国家癌症登记处数据库中 2010-2020 年期间确诊的癌症病例记录(n = 1,498,911);数据将于 2022 年初提交。通过连接点回归程序估算了 2010-2019 年年龄标准化发病率的趋势:2010-2019 年间,男性结肠癌、前列腺癌和咽癌的发病率上升(p < 0.05),女性结肠癌、甲状腺癌和胰腺癌的发病率上升(p < 0.05),其他流行癌症的发病率保持稳定或下降(男性肺癌和喉癌,女性宫颈癌和直肠癌,男女胃癌);发病率的上升主要以 60-74 岁人群为代价。癌症发病率明显下降的是 40-59 岁的男性。2020 年,COVID-19 的爆发对及时发现癌症产生了严重的负面影响,这种影响发生在乌克 兰人口的所有成年年龄组,涉及所有最常见的癌症。非黑色素瘤皮肤癌的发病率下降最为明显(35.9%-37.9%);其他流行癌症的发病率下降幅度不等,男性从-23.0%(前列腺)到-9.7%(咽部)不等,女性从-21.2%(肾脏)到-9.1%(胰腺)不等,其中75 岁以上人口的下降幅度最大:2020 年乌克兰癌症发病率的急剧下降显然是由于医疗保健设施有限,以及大流行病期间主要关注 COVID-19 导致人们对肿瘤的警觉性降低。然而,这并不是癌症发病率下降的表现。在接下来的几年中,这可能会增加晚期诊断的比例、癌症治疗系统的负担以及乌克兰人口的癌症死亡率。需要进一步监测 COVID-19 大流行对乌克兰癌症负担的短期和长期影响。
{"title":"СANCER INCIDENCE IN UKRAINE: TRENDS IN 2010-2019 AND THE IMPACT OF COVID-19 PANDEMIC.","authors":"Yu I Michailovich, O V Sumkina, Ye L Gorokh","doi":"10.15407/exp-oncology.2023.04.463","DOIUrl":"10.15407/exp-oncology.2023.04.463","url":null,"abstract":"<p><strong>Background: </strong>In 2020, a sharp decrease in the number of new cancer cases was registered in Ukraine in the setting of the quarantine restrictions due to the COVID-19 pandemic, which contrasted with the previous trends.</p><p><strong>Aim: </strong>To study trends of cancer incidence rates in Ukraine in the recent decade and to assess the impact of COVID-19 pandemic on cancer detection in 2020.</p><p><strong>Materials and methods: </strong>Records on cancer cases diagnosed during 2010-2020 (n = 1,498,911) from the database of the National Cancer Registry of Ukraine were used; the data being submitted early in 2022. Trends of the age-standardized incidence rates in 2010-2019 were estimated by the Joinpoint Regression Program.</p><p><strong>Results: </strong>During 2010-2019, the incidence rates increased (p < 0.05) for colon, prostate, and pharyngeal cancers in males and for colon, thyroid, and pancreas in females with the rates of other prevalent cancers being stable or decreasing (lung and larynx in males, cervix and rectum in females, stomach in both genders); the incidence increased mainly at the expense of the population aged 60-74 years. A significant decrease in cancer incidence was in males aged 40-59 years. In 2020, the serious negative impact of COVID-19 outbreak on the timely detection of cancer occurred in all adult age groups of the Ukrainian population and involved all the most common cancers. The most pronounced diminution of the incidence rate was observed for non-melanoma skin cancers (by 35.9%- 37.9%); the decrements of the rates for other prevalent cancers varied from -23.0% (prostate gland) to -9.7% (pharynx) in males and from -21.2% (kidney) to -9.1% (pancreas) in females, the greatest ones being in the population aged 75+.</p><p><strong>Conclusions: </strong>The sharp drop of the cancer incidence rates registered in Ukraine 2020 is evidently the result of the limited access to healthcare facilities as well as the reduced oncological alertness of the population due to the predominant focus on COVID-19 during the pandemic. However, it is not a manifestation of a decrease in cancer incidence as such. In the following years, this may increase the proportion of advanced-stage diagnoses, the load on the cancer care system, and cancer mortality in the Ukrainian population. An evaluation of the short-termand long-term effects of the COVID-19 pandemic on the cancer burden in Ukraine requires further monitoring.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MANEC TUMOR OF RECTUM. A RARE CASE SERIES OF 3 PATIENTS AND A LITERATURE REVIEW. 直肠 manec 肿瘤。3例患者的罕见病例系列和文献综述。
Pub Date : 2024-02-03 DOI: 10.15407/exp-oncology.2023.04.523
R Govindaraj, Sh Govindaraj, C Prakash, S Govindaraj

The term Mixed Adeno-Neuro-Endocrine Carcinoma (MANEC) was introduced in 2010 by the WHO Classification of Tumors of the Digestive System. It refers to a neoplasm with dual epithelial and neuroendocrine differentiation, each component representing at least 30% of the tumor. It is an uncommon tumor accounting for < 3% of all colon and rectum malignancies. We report three cases of this extremely rare MANEC of the rectum. All three cases presented with hematochezia, variable constipation, and abdominal pain. They were diagnosed and staged appropriately with colonoscopy, biopsy with immunohistochemistry, and imaging. They underwent an anterior resection with circular stapled anastomoses. Because of the low incidence of this histotype, we reviewed the clinical presentation, diagnostic characteristics, and treatment of MANEC of the colon and rectum.

世卫组织消化系统肿瘤分类》于 2010 年引入了 "腺-神经-内分泌混合癌"(MANEC)一词。它是指具有上皮和神经内分泌双重分化的肿瘤,每种成分至少占肿瘤的 30%。它是一种不常见的肿瘤,在所有结肠和直肠恶性肿瘤中占比小于 3%。我们报告了三例这种极其罕见的直肠MANEC。这三个病例均伴有血便、不同程度的便秘和腹痛。通过结肠镜检查、免疫组化活检和影像学检查,对他们进行了适当的诊断和分期。他们接受了前部切除术,并进行了环形缝合吻合。由于这种组织类型的发病率较低,我们回顾了结肠和直肠 MANEC 的临床表现、诊断特点和治疗方法。
{"title":"MANEC TUMOR OF RECTUM. A RARE CASE SERIES OF 3 PATIENTS AND A LITERATURE REVIEW.","authors":"R Govindaraj, Sh Govindaraj, C Prakash, S Govindaraj","doi":"10.15407/exp-oncology.2023.04.523","DOIUrl":"10.15407/exp-oncology.2023.04.523","url":null,"abstract":"<p><p>The term Mixed Adeno-Neuro-Endocrine Carcinoma (MANEC) was introduced in 2010 by the WHO Classification of Tumors of the Digestive System. It refers to a neoplasm with dual epithelial and neuroendocrine differentiation, each component representing at least 30% of the tumor. It is an uncommon tumor accounting for < 3% of all colon and rectum malignancies. We report three cases of this extremely rare MANEC of the rectum. All three cases presented with hematochezia, variable constipation, and abdominal pain. They were diagnosed and staged appropriately with colonoscopy, biopsy with immunohistochemistry, and imaging. They underwent an anterior resection with circular stapled anastomoses. Because of the low incidence of this histotype, we reviewed the clinical presentation, diagnostic characteristics, and treatment of MANEC of the colon and rectum.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1